0001209191-23-030446.txt : 20230517
0001209191-23-030446.hdr.sgml : 20230517
20230517202707
ACCESSION NUMBER: 0001209191-23-030446
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230516
FILED AS OF DATE: 20230517
DATE AS OF CHANGE: 20230517
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROBIN HOWARD W
CENTRAL INDEX KEY: 0001206869
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24006
FILM NUMBER: 23933491
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS
CENTRAL INDEX KEY: 0000906709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943134940
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 4154825300
MAIL ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC
DATE OF NAME CHANGE: 19980723
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS
DATE OF NAME CHANGE: 19940303
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-16
0
0000906709
NEKTAR THERAPEUTICS
NKTR
0001206869
ROBIN HOWARD W
C/O NEKTAR THERAPEUTICS
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO
CA
94158
1
1
0
0
President & CEO
0
Common Stock
2023-05-16
4
S
0
20361
0.72
D
939797
D
Common Stock
410
I
by spouse
Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
This transaction was executed in multiple trades at prices ranging from $0.71 to $0.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer.
Mark A. Wilson
2023-05-17